Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study

CONCLUSIONS: Among AF patients anticoagulated with rivaroxaban, HF patients had a worse clinical profile and a higher MACE risk and cardiovascular mortality. HF was independently associated with the development of MACE, but not with thromboembolic events or major bleeding.PMID:36200548 | DOI:10.5603/CJ.a2022.0091

Source: Cardiology Journal - October 6, 2022 Category: Cardiology Authors: Manuel Anguita S ánchez Francisco Mar ín Jaime Masjuan Juan Cos ín-Sales Jos é Manuel Vázquez Rodríguez Vivencio Barrios Gonzalo Bar ón-Esquivias I ñaki Lekuona Alejandro I P érez-Cabeza Rom án Freixa-Pamias Francisco Javier Parra Jimenez Mohame Source Type: research